1. Generics Bulletin
  2. >>Legal & IP

Teva Prepares To Fight Appeal After US Narcan Victory

Four Patents For Naloxone Spray Invalidated By District Court, But Appeal Looms

 
• By Dave Wallace

Teva has won a US district court victory invalidating four patents protecting the Narcan naloxone nasal spray. However, despite holding FDA approval for a generic, the Israeli firm believes the battle is far from over.

Naloxone
The ruling invalidated four Narcan patents • Source: Shutterstock

Teva says a US district court victory that has seen the company successfully invalidate four patents protecting Adapt Pharma’s Narcan (naloxone) nasal spray may clear the way for it to launch its approved generic version of the opioid overdose treatment.

However, the Israeli firm believes the battle is far from over, with an appeal from Adapt parent Emergent BioSolutions on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Generics Bulletin

Iron Sucrose Competition Expands With Viatris and Amphastar FDA Approvals

 
• By Dean Rudge

Viatris and Amphastar are expanding their complex generic portfolios with the planned launches of FDA-approved versions of Vifor Pharma/Daiichi Sankyo’s Venofer (iron sucrose). The FDA’s database also show Sandoz holds an approval for generic Venofer, though it has not disclosed launch plans.

Generic Drugs And AI: Maximum Daily Dose Tool Could Help US FDA Be ‘At The Forefront’

 
• By Michael McCaughan

The FDA is testing a new artificial intelligence tool to help generic drug developers automate maximum daily dose calculations.

Amgen Welcomes Evolving Biosimilar Guidelines As Competitive Advantage

 
• By Dean Rudge

Amgen sees potential regulatory shifts toward streamlined biosimilar approvals as favorable, citing its strength in developing high-quality products.